Search Results
38 Results Found for “trastuzumab deruxtecan”
Metastatic triple-negative breast cancer (mTNBC) is a clinically heterogeneous disease, but compared with other breast cancer subtypes, triple-negative breast cancer (TNBC) is generally associated with a poorer prognosis and has historically had limited therapeutic options.1 The 5-year survival rate remains ...
The 2026 World Conference on Lung Cancer delivered several results with the potential to change clinical practice. My main takeaway was the speed at which effective options are multiplying in both small-cell lung cancer and molecularly defined non-small-cell lung cancer. The immediate advance is welcome, but it also makes treatment selection more complex: mature survival, intracranial control, toxicity, sequencing and access will increasingly matter as much as response rate or progression-free survival.
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1 Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
February has already been very busy across regulation, clinical research and community awareness - and we're only half way through! See below a round-up of the main breakthroughs and what to look out for during the rest of the month. ...
Breakthroughs from the 2025 San Antonio Breast Cancer Symposium in oral SERDs, HER2-targeted maintenance therapy, ADCs and next-generation endocrine combinations are reshaping breast cancer care across early and metastatic disease. From practice-changing phase III data to nuanced treatment selection in triple-positive and ESR1-mutant disease, this in-depth report unpacks what the latest trials really mean for clinicians. Register now to read the full analysis and stay ahead of rapidly evolving practice.
“ESMO 2025 felt like a true turning point in breast cancer care” At the European Society for Medical Oncology (ESMO) 2025 congress, the landscape of early and advanced breast cancer management was powerfully reshaped, with new data spanning hormone-receptor positive (HR+), human ...
Cervical cancer (CC) is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 CC-related deaths in 2020.1# Approximately 90% of CCs are caused by infection with human papillomavirus (HPV).2 Even though the adoption of both primary (HPV ...
The first half of 2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, EHA and many more leading conferences around the world. We asked five of our touchONCOLOGY Future Leaders 2025 to share what they believe has been most impactful so far this year – here’s what they told us.
At ASCO 2025, cervical cancer took centre stage in gynecologic oncology with data showing how immunotherapy is redefining the treatment landscape. Trials such as KEYNOTE-826 and KEYNOTE-A18 demonstrated meaningful gains in survival, while emerging antibody–drug conjugates point to a new wave of personalised therapy for this historically underserved disease.
ASCO 2025 showcased transformative breast cancer data. The SERENA-6 trial introduced a novel ctDNA-driven approach for ESR1 mutations, improving PFS with camizestrant. DESTINY-Breast09 supported trastuzumab deruxtecan in first-line HER2-positive disease, while ASCENT-04 showed promise for sacituzumab govitecan plus immunotherapy in triple-negative breast cancer—heralding major shifts in clinical practice.
DESTINY-Breast09 interim results show that trastuzumab deruxtecan plus pertuzumab significantly improves progression-free survival compared to standard THP in first-line treatment for metastatic HER2-positive breast cancer. With a median PFS of 40.7 months versus 26.9 months, the data suggest a potential shift in the treatment paradigm.
Head and neck cancer (HNC), with over 946,000 new cases and 482,000 deaths in 2022, is the seventh most common cause of cancer-related deaths globally.1 Specifically, in the USA, the number of estimated new cases in 2024 was 74,000.2 Head and neck squamous cell carcinoma (...
he DESTINY-Breast06 (DB-06) trial explored the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with hormone receptor-positive (HR+), HER2-low or HER2-ultralow metastatic breast cancer (mBC). Patients were screened for HER2 status and randomized to receive either T-DXd or treatment of the physician's choice (TPC). Results showed that T-DXd significantly improved progression-free survival (PFS) compared to TPC, across various HER2 classifications.
The annual ASCO2024 meeting was packed as always with the latest trial data and treatment advances in oncology.
Providing valuable insights into the findings from key studies including DESTINY-Breast06 (NCT04494425), postMONARCH (NCT05169567), and TBCRC 048 (olaparib expanded) (NCT02032823), Dr. Tolaney explores the potential impact these results could have on clinical practice.
Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and ...
Trastuzumab deruxtecan (T-DXd) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) designed to effectively deliver a potent topoisomerase I inhibitor (exatecan derivative) to HER2-expressing cancer cells and limit potential systemic toxicity.1 T-DXd has ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
